📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A Phase II, Open-label study to assess safety and management change using 68Ga-THP PSMA PET/CT in patients with high risk primary prostate cancer or biochemical recurrence after radical treatment: The PRONOUNCED study. (2021)

First Author: Afaq A

Attributed to: Next generation molecular imaging and therapy with radionuclides funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.2967/jnumed.120.257527

PubMed Identifier: 33741648

Publication URI: http://europepmc.org/abstract/MED/33741648

Type: Journal Article/Review

Volume: 62

Parent Publication: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Issue: 12

ISSN: 0161-5505